Floatz logo

ly3321367

Microsatellite Instability-High (MSI-H) Solid Tumors

Eli Lilly and CompanyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Microsatellite Instability-High (MSI-H) Solid Tumors cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Eli Lilly and Company
Phase 1CC
Abemaciclib
Eli Lilly and Company
Phase 1CC
LODAPOLIMAB
Eli Lilly and Company
Phase 1CC
Nivolumab
Eli Lilly and Company
Phase 1CC
Merestinib
Eli Lilly and Company
Phase 1CC

Same molecule, other indications

ly3321367 is also rated in:

breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
44 / 100
View asset →
neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →